$2.9 billion in sales forecast for BMS' Sotyktu by 2029

11 May 2023

The recent European Commission approval for Sotyktu (deucravacitinib), US pharma major Bristol Myers Squibb’s (NYSE: BMY) first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for adults with moderate-to-severe plaque psoriasis (PsO), has elicited comment from data and analytics firm, GlobalData.

Representing a new class of small molecules with a unique mechanism of action, Sotyktu is set to become a blockbuster for the treatment of PsO with a global sales forecast of $2.9 billion by 2029, according to GlobalData. BMS itself is even more optimistic, forecasting sales of the drug, which was approved in the USA in September 2022, will reach $4 billion by 2029.

BMS acquired Sotyktu along with its acquisition of Celgene in 2019 for $74 million, and opted to keep it rather than already-approved Otezla (apremilast) which, because of competition issues, was sold on to Amgen (Nasdaq: AMGN) for $13.4 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK